

REGISTERED COMPANY NUMBER: 08031174
REGISTERED CHARITY NUMBER: 1147658

FUNGAL INFECTION TRUST

REPORT AND ACCOUNTS

30 APRIL 2022

FUNGAL INFECTION TRUST

INDEX

Page

1	Reference and administrative details
2-7	Trustees' Report
8	Independent examiner's report
9	Statement of financial activities
10	Balance Sheet
11-15	Notes to the accounts
16-17	Appendix
	Scientific publications and presentations

FUNGAL INFECTION TRUST

REFERENCE AND ADMINISTRATIVE DETAILS

Trustees	Professor P J Folkman Mr P G Oxnam Mr J C Morgan Dr C Pankhurst Professor J Cooke Professor R Hay
Hon Secretary	Mr J C Morgan
Bankers	Royal Bank of Scotland 56 Chestergate Macclesfield Cheshire SK11 6BA
Independent Examiner	Roslyn Beattie Company Solutions Limited 2 Festival Square Little Germany Bradford BD1 5BD
Registered Address	P.O. Box 482, Macclesfield Cheshire SK10 9AR
Charity Registration:	1147658
Company Registration:	08031174

FUNGAL INFECTION TRUST

TRUSTEES' REPORT

The board of Trustees, who are also directors of the Charity for the purposes of the Companies Act 2006, present their report and financial statements of Fungal Infection Trust for the year ended 30 April 2022. The financial statements have been prepared in accordance with the accounting policies as set out on page 11 and comply with the charity's trust deed, the Companies Act 2006 and the Statement of Recommended Practice – Accounting and Reporting by Charities 2011.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Fungal Infection Trust ("The Charity" or "The Trust" or "FIT") is a company limited by guarantee and governed by its Memorandum and Articles of Association.

DIRECTORS AND TRUSTEES

The directors of the charitable company are its Trustees for the purpose of charity law and throughout this report are collectively referred to as the **Trustees**.

The Trustees serving during the year were as follows:

Mr P G Oxnam **Chairman**

Mr J C Morgan **Secretary**

Professor J Cooke (resigned 5 October 2022)

Professor P J Folkman

Professor R Hay

Dr C L Pankhurst

New trustees are interviewed and appointed by the existing trustees. Before taking up their positions, new trustees are sent on externally run training courses where appropriate.

Risk Management

The Trustees have examined the major strategic, business and operational risks which the charity faces and confirm that systems have been established to enable regular reports to be produced so that the necessary steps can be taken to lessen these risks.

Organisational Structure and Governance

The Trust is managed by the Trustees. The Trust has no paid or voluntary employees. Accounts are prepared by the Secretary on a regular basis and presented to the Trustees at their meetings. The financial status of the Trust is reviewed by a Trustee sub-committee prior to each Trustees' meeting and its recommendations presented to the meeting. A minimum of three Trustees meetings are held each year.

Responsibilities of Trustees

Law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the incoming resources and application of the resources of the charity during the year and of its state of affairs at the end of the year. In preparing financial statements giving a true and fair view, the trustees recognise they should follow best practice and:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards and statements of recommended practice have been followed;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy the financial position of the charity and which enable them to ascertain its financial position and to ensure that the financial statements comply with the Companies Act 2006 and the Statement of Recommended Practice – Accounting and

FUNGAL INFECTION TRUST

TRUSTEES' REPORT

Reporting by Charities 2005 and the Trust Deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

OBJECTIVES AND ACTIVITIES

1. To promote research in all aspects of mycology, mycotic diseases, fungal toxicology and microbial disease (of all living things) and to publish the useful results thereof.
2. To advance education particularly among physicians and scientists about mycology, mycotic diseases, fungal toxicology and microbial diseases in general.
3. To generally support basic research into fungi and fungal disease, train scientists in mycology and related disciplines.
4. To provide information to patients suffering from fungal diseases, in particular aspergillosis.
5. To raise awareness of fungal pathogens and fungal diseases amongst the general public in the UK and internationally.

Review of Activities

The FIT website (www.fungalinfectiontrust.org) averaged ~640 (range 528 – 764) unique visitors per month in late 2021 and 2022. The most popular pages are What we do, Research Grants and Fungal Disease Awareness Week.

Online education in fungal microscopy and histology (www.microfungi.net/)

The FIT continues to support the world's first online Microscopy and Histology course (Microfungi). To date this course has hosted 2,200 distinct users from 132 countries (an increase from 1849 the previous year). The key participants have been from the United Kingdom, Mexico, Brazil, USA, India, Nigeria, Argentina, Colombia, Spain, and Ghana. Currently this course is available in English, Spanish, French, Portuguese and Chinese. So far 470 pass or distinction certificates have been awarded. All those registered on the course can re-enter the course to refresh their knowledge at any point. This makes Microfungi an invaluable life-long learning tool for all healthcare practitioners. Typically 5 – 15 users' login each day.

The Aspergillus Website @ www.aspergillus.org.uk

The Aspergillus Website has been in operation since 1998, so this is its 24th year of operation. The Aspergillus Website remains the world's most comprehensive resource for the pathogenic and allergenic fungi Aspergillus and the diseases that they cause. It is completely free to all users. It has been supported by unrestricted educational grants from various corporate donors, notably Pfizer, Dynamiker and Gilead.

The Aspergillus Website was moved from the obsolete operating system it was based on in late September 2020, so this is the end of its second year on its new platform in WordPress – a move made possible by the continuing success and expansion of that system worldwide and its improved ability to run a website the size of the Aspergillus Website. It has run consistently well on WordPress over the two years.

A drawback of moving the underlying content management system (CMS) of any website is that almost all of the links are changed, which means that all searches in any search engine become out of date overnight. As many visitors to most websites arrive as a result of Google and Bing searches (and others) this means that overall user number sharply drops. In the case of the Aspergillus Website it dropped from an average of 1000 users per day to 400 users per day.

Steps were taken to ensure the new website links would be taken up by search engines as quickly as possible and the number of users rose to 500 per day by end of 2020. The increase continued up until summer 2021 but has dropped in early 2022.


The Aspergillus Website is still read very widely across the world, with (in order of usage, highest to lowest) China, USA, UK, India and Australia making up 65% of users. China, USA UK, India, Australia, Germany Canada, Philippines, France and Russia are the most frequent users. The prominence of two non-English speaking countries in the top 6 (and 4 more in the top 10) may reflect our decision to add in automatic language translation of the entire website when the website was moved to WordPress.

The Aspergillus Website provides free easy access to >74,000 pages, over 15,400 scientific articles (including a unique collection of 836 historical articles) and over 17,200 conference abstracts from 1974 onwards. The Aspergillus Website has been mostly viewed on desktop PC (66%) rather than mobile (33%) in 2022, possibly reflecting the professional nature of its users and most of the rest of the world use mobile phones to browse websites.

FUNGAL INFECTION TRUST

TRUSTEES' REPORT

Fig 1. 90 days Feb-April 2022



The comprehensive list of drugs and drug interactions with antifungals is continually updated. The drug interaction database (www.aspergillus.org.uk/antifungal-drug-interactions/) (including the antifungal drug interaction app for android phones) is popular and well used. Links from other websites to this specific part of the website have been added.


Leading International Fungal Education (LIFE) (www.LIFE-Worldwide.org) (June 2021- May 2022)

The LIFE Worldwide website recorded 103k users during this period with 119k individual visits. This figure is down on 2020/21 as we began to migrate content away from this platform on to the new www.fungaleducation.org site. We estimate that this traffic will transfer across to the new site during 2022/23 and we will see a steady growth in users as we market these new resources. We launched the new platform www.fungaleducation.org in 2022. Work is ongoing to add and develop content for the new site. It was widely promoted at the international ECCMID meeting in Lisbon. 20022/23 will focus on further marketing the platform and targeting specific global audiences.

The Spanish pages continue to be popular and well-used indicating a need for us to present the website in multiple languages.

FUNGAL INFECTION TRUST

TRUSTEES' REPORT



Over the last 90 days we have recorded over 700 users on the new site, with around 45% of these accessing the Spanish version of the site.

Our YouTube channel continues to be an impactful part of the LIFE Worldwide educational offering. As well as adding three new videos on drug/drug interactions we also had the exceptional milestone of one of our videos passing 100,000 views. Over the year our channel has received 105,000 watches, equating to almost 4,000 hours of viewing time. Our top 5 countries by audience are India (35%), United States (13%), Bangladesh (4%), Pakistan (3%) and Philippines (2%).

LIFE Worldwide continues to make a substantial impact on Twitter. During 2021/22 our Tweets received over 192,000 impressions, and we saw a steady growth of followers (20.5% growth over the year). The Tweet with the biggest impact was promoting the Center For Disease Control's Fungal Disease Awareness Week. We are using this data to build a marketing calendar for 2022/23 to utilise the various global awareness days and to use these to raise our profile.

A component of the LIFE effort has been to boost awareness of fungal infections generally, by quantifying the problem better. This has involved estimating the burden of serious fungal disease in over 100 countries, to highlight the seriousness of a range of primary and secondary fungal diseases. Additions since last year's report are underlined.

- Published in journals (x81): Algeria, Argentina, Austria, Azerbaijan, Bangladesh, Belgium, Brazil, Burkina Faso, Cameroon, Canada, Chile, China, Colombia, Congo (Republic of), Cote d'Ivoire, Czech Republic, Democratic Republic of Congo (DRC), Denmark, Dominican Republic, Ecuador, Egypt, Eritrea, Ethiopia, France, Germany, Ghana, Greece, Guatemala, Honduras, Hungary, India, Indonesia, Iran, Ireland, Israel, Italy, Jamaica, Jordan, Kazakhstan, Kenya, Kuwait, Kyrgyzstan, Malawi, Malaysia, Mexico, Morocco, Mozambique, Namibia, Nepal, Netherlands, Nigeria, Norway, Oman, Pakistan, Peru, Philippines, Portugal, Qatar, Romania, Russia, Senegal, Serbia, Sierra Leone, South Africa, Spain, Sri Lanka, Sweden, Taiwan, Tajikistan, Tanzania, Thailand, Togo, Trinidad and Tobago, Turkey, Uganda, UK, Ukraine, Uruguay, Uzbekistan, Vietnam and Zimbabwe. Published burden papers are available at <https://www.gaffi.org/media/academic-papers/>.
- Presented in abstract/poster form at conferences but not yet published (x13): Australia, Belarus, Benin, Iraq, Japan, Madagascar, Mongolia, New Zealand, Paraguay, Saudi Arabia, Singapore, Venezuela, Zambia (detail is available on the LIFE website in the news section <http://www.life-worldwide.org/media-centre/news>).

Top media Tweet earned 5,468 impressions


It's @CDCgov Fungal Disease Awareness Week. Throughout the week we'll be highlighting relevant resources for you to access to learn more about the global impact of fungal diseases.

#thinkfungus #meded #fungalinfection
#awareness #education #research
#mycology pic.twitter.com/qV3ZBpxh7D



FUNGAL INFECTION TRUST

TRUSTEES' REPORT



The FIT also supported several important research publications and reviews (see Appendix). There were 15 peer-reviewed publications in calendar year 2021 as a direct consequence of FIT grants and collaborations. The notable outputs include:

- Two papers describing the diagnostic performance of the new point of care assay for *Aspergillus* antibody – related to subtle immunodeficiency and in Indonesia,
- Country burden of disease estimates for 6 countries in 2021, including 2 highly populous countries – DRC and Indonesia,
- A review of antifungal drug interactions, linked to the online database: www.aspergillus.org.uk/antifungal-drug-interactions/
- Two papers related to how professional phagocytes in the body actually kill *Aspergillus* fungi.

During the year support was given to research projects at the University of Perugia, Italy; the Medical Research Foundation, Trinidad and Tobago; the University of Lomé, Togo; the Université de Montagnes, Banganté, Cameroon. Travel and Living Allowance Grants for attendance and presentation at scientific conferences totalling £780 (2021 Nil) were made during the year as part of the Trust's policy to support scientists in the early stages of their careers in mycology.

Who benefited from the Trust's Activities?

Researchers in the study of fungi (mycology), respiratory medicine and infectious diseases from all over the world
Medical doctors, especially through the Drug Interactions database

Patients and their carers.

Students of medicine, pharmacy, biology and microbiology

The public – school children, their teachers and parents.

How do the Trust's Activities Benefit the Public?

Awareness of fungal disease remains low among the general public. The FIT website enables the public to access reliable information quickly on this topic, augmented by the more specialised web resources at LIFE-Worldwide and the *Aspergillus* Website. The rebranded FIT website also re-posts press and general stories and explanatory articles for easy access for all.

Future plans

In 2022, an update and overhaul of the Microfungi educational website is planned. Efforts to promote the FIT resources internationally are planned at major conferences in Europe, USA, Asia and Africa. The *Aspergillus* Website continues

FUNGAL INFECTION TRUST

TRUSTEES' REPORT

to provide a valuable resource internationally, with some additional content. The FIT will respond to grant requests as it has done previously.

FINANCIAL REVIEW,

The results for the period are set out on page 9. There was a deficit of Income over Expenditure for the year of £70,200, (2021 £36,150). Corporate Governance expenditure represented 20.70% of total income (2021 14.50%). During the year the re-design of the Fungal Infection Website was completed at a cost of £1,200. As a result of the restrictions placed upon us because of the COVID-19 Pandemic all Trustees meetings were held using Zoom as a consequence no Trustees Expenses or Meeting Costs were incurred.

Investment Policy

The trustees do not consider that they have sufficient free reserves to invest surplus funds for any medium to long term. Consequently, funds are maintained in a bank deposit account

Reserves Policy

The charity have established a policy to maintain unrestricted funds not committed or invested in fixed assets i.e. 'free reserves' at a level of between one and two years of unrestricted expenditure. This provides sufficient levels of funds to be able to continue the current activities of the charity and to provide sufficient time to consider and replace existing funding sources should there be a significant change in present funding arrangements.

The reserves policy is reviewed annually.

Secretariat

The Trustees wish to express their appreciation of the work undertaken by Mr J Morgan in running the secretariat and administrative functions of the Trust during the past year.

Independent Examiner

In accordance with the Trust Deed, a proposal to re-appoint Company Solutions Limited for the forthcoming year will be put to the general meeting.

On behalf of the Trustees

Phillip Oxnam

5 October 2022



FUNGAL INFECTION TRUST

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF FUNGAL INFECTION TRUST

I report to the trustees on my examination of the financial statements of Fungal Infection Trust (the charity) for the year ended 30 April 2022.

Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charity's financial statements carried out under section 145 of the Charities Act 2011 (the 2011 Act).


In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connect with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of the independent examination; or
- 4 the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Roslyn Beattie FCA
Company Solutions Limited

Date 8 October 2022

FUNGAL INFECTION TRUST

STATEMENT OF FINANCIAL ACTIVITIES PERIOD ENDED 30 APRIL 2022

	Note	General Unrestrict ed funds 2022 £	Designated funds 2022 £	Total funds Year to 30 April 2022 £	Total funds Year to 30 April 2021 £
INCOMING RESOURCES					
Incoming resources from generated funds					
Voluntary income:					
Donations and grants	2	20,918	-	20,918	17,535
Activities for generating funds:					
Investment income	3	30	-	30	48
Incoming resources from charitable activities					
Donations and grants	4	-	11,435	11,435	119,503
TOTAL INCOMING RESOURCES		<u>20,948</u>	<u>11,435</u>	<u>32,383</u>	<u>137,086</u>
RESOURCES EXPENDED					
Costs of charitable activities					
Charitable activities	5	40,091	55,789	95,880	153,359
Governance costs	5	6,703	-	6,703	19,877
TOTAL RESOURCES EXPENDED		<u>46,794</u>	<u>55,789</u>	<u>102,583</u>	<u>173,236</u>
NET MOVEMENT IN FUNDS		-25,846	-44,354	-70,200	-36,150
Transfers between funds		-	-	-	-
Total Funds brought forward		<u>105,217</u>	<u>116,215</u>	<u>221,432</u>	<u>257,582</u>
TOTAL FUNDS CARRIED FORWARD		<u>79,371</u>	<u>71,861</u>	<u>151,232</u>	<u>221,432</u>

The statement of financial activities includes all gains and losses recognised in the period.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements of an income and expenditure account under the Companies Act 2006.

FUNGAL INFECTION TRUST

BALANCE SHEET AS AT 30 APRIL 2022

		£	2022 £	£	2021 £
	Note				
CURRENT ASSETS					
Debtors	8	7,900		26,162	
Cash at bank		163,580		229,181	
		<u>171,480</u>		<u>255,343</u>	
CREDITORS					
Amounts falling due within one year	9	20,248		33,911	
		<u>20,248</u>		<u>33,911</u>	
NET CURRENT ASSETS			<u>151,232</u>		<u>221,432</u>
NET ASSETS			<u>151,232</u>		<u>221,432</u>
ACCUMULATED FUNDS					
Restricted funds					
Designated funds	10		71,861		116,215
General unrestricted funds	11		79,371		105,217
			<u>151,232</u>		<u>221,432</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 30 April 2022.

The Trustees have not required the charitable company to obtain an audit of its financial statements for the period ended 30 April 2022 in accordance with Section 476 of the Companies Act 2006.


The Trustees acknowledge their responsibilities for:

- a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.


These financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small charitable companies and with the Financial Reporting Standard for Smaller Entities (effective April 2008).

The financial statements were approved by the Board of Trustees on 22nd September 5th October 2022 and were signed on its behalf by:

Mr J C Morgan



Mr P Oxnam



FUNGAL INFECTION TRUST
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 30 APRIL 2022

CHARITY INFORMATION

Fungal Infection Trust is a private company limited by guarantee incorporated in England and Wales. The registered office is P.O.B 482, Macclesfield, Cheshire, SK10 9AR

1. ACCOUNTING POLICIES

The principal accounting policies adopted, judgements and key sources of estimation of uncertainty in the preparation of the financial statements are as follows:

a) Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

FIT meets the definition of a public benefit entity under (FRS 102). Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

b) Going Concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus, the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

c) Fund Structure

The charity maintains the following types of funds:

Designated funds represent grants, donations and legacies received which are allocated by the donor for specific purposes.

General unrestricted fund represents unrestricted income which is expendable at the discretion of the trustees in the furtherance of the objects of the charity. Such a fund may be held in order to finance both working capital and capital investment.

There are no restricted funds in the Charity.

d) Incoming Resources

All incoming resources are recognised once the charity has entitlement to the resources, it is certain that all the resources will be received and the monetary value of incoming resources can be measured with sufficient reliability.

FUNGAL INFECTION TRUST

NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 30 APRIL 2022

e) Resources Expended

Expenditure is recognised on an accrual basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is reported as part of the expenditure to which it relates:

- Costs of generating funds comprise the costs associated with attracting voluntary income.
- Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them. This expenditure includes all expenditure directly related to the objects of the charity.
- Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charity and include the independent examiner's fees and costs linked to the strategic management of the charity.

f) Taxation

The charity is exempt from corporation tax on its charitable activities.

2. DONATIONS AND GRANTS

	General Unrestricted Funds 2022 £	Designated Funds 2022 £	Total funds Year to 30 April 2022 £	Total funds Year to 30 April 2021 £
General donations	20,918	-	20,918	17,535

General donations include sundry amounts donated to the charity by members of the public. No gifts in kind have been received in either the current or previous year.

3. ACTIVITIES FOR GENERATING FUNDS

INVESTMENT INCOME

	General Unrestricted Funds 2022 £	Designated Funds 2022 £	Total funds Year to 30 April 2022 £	Total funds Year to 30 April 2021 £
Bank interest	30	-	30	48

FUNGAL INFECTION TRUST

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 30 APRIL 2022

4. INCOMING RESOURCES FROM CHARITABLE ACTIVITIES

DONATIONS AND GRANTS

	General Unrestricted Funds 2022 £	Designated Funds 2022 £	Total funds Year to 30 April 2022 £	Total funds Year to 30 April 2021 £
Gilead	-	7,900	7,900	23,700
Pfizer	-	-	-	34,625
Zambon	-	-	-	17,009
Mayne Pharma	-	-	-	11,042
Huskisson	-	-	-	31,250
Dynamiker	-	3,535	3,535	-
Sundry	-	-	-	1,877
	-			
	-	11,435	11,435	119,503

5. COSTS OF CHARITABLE ACTIVITIES

	Note	General Unrestricted funds 2022 £	Designated funds 2022 £	Total funds Year to 30 April 2022 £	Total funds Year to 30 April 2021 £
Donations and grants		40,091	42,763	82,854	118,385
Project costs	6	-	13,026	13,026	34,974
Travel grants		-	-	-	-
Governance costs	7	6,703	-	6,703	19,877
		46,794	55,789	102,583	173,236

FUNGAL INFECTION TRUST

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 30 APRIL 2022

6. COSTS OF CHARITABLE ACTIVITIES

PROJECT COSTS

	General Unrestricted funds 2022 £	Designated funds 2022 £	Total funds Year to 30 April 2022 £	Total funds Year to 30 April 2021 £
University of Manchester Research Team	-	(10,000)	(10,000)	10,000
Other activity costs	-	23,026	23,026	24,974
	-	13,026	13,026	34,974

7. GOVERNANCE COSTS

	General Unrestricted funds 2022 £	Designated funds 2022 £	Total funds Year to 30 April 2022 £	Total funds Year to 30 April 2021 £
Insurance	810	-	810	810
Legal and professional	13	-	13	13
Travel and meeting costs	150	-	150	0
Printing/postage/stationery	458	-	458	681
Accountancy fees	1,200	-	1,200	1,150
Bank charges	162	-	162	138
Promotion Costs	-	-	-	953
FIT Website Costs	3,910	-	3,910	16,132
	6,703	-	6,703	19,877

8. DEBTORS

	2022 £	2021 £
Invoiced	7,900	26,162

9. CREDITORS: Amounts falling due within one-year

	2022 £	2021 £
Accruals	20,248	33,911

FUNGAL INFECTION TRUST

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 30 APRIL 2022

10. MOVEMENT IN DESIGNATED FUNDS

	1 May 2021 £	Income £	Expenditure, Gains, losses & Transfers £	30 April 2022 £
Aspergillus Website	84,965	11,435	13,026	83,374
Stella Huskisson Memorial Fund	31,250	0	0	31,250
LIFE-Worldwide	0	0	42,763	(42,763)
	<u>116,215</u>	<u>11,435</u>	<u>55,789</u>	<u>71,861</u>

11. RECONCILIATION OF MOVEMENTS IN GENERAL FUNDS

	<u>2022</u> £	<u>2021</u> £
Deficit (2021 surplus) of income over expenditure for the year	-25,846	25,771
Funds at the beginning of the year	105,217	79,446
Funds to carry forward	<u>79,371</u>	<u>105,217</u>

12. ANALYSIS OF ASSETS AND LIABILITIES BETWEEN FUNDS

	General Unrestricted funds £	Designated funds £	Total funds 2022 £
Current assets			
Cash at bank and in hand	92,917	70,663	163,580
Debtors	-	7,900	7,900
Current liabilities	-13,546	-6,702	-20,248
	<u>79,371</u>	<u>71,861</u>	<u>151,232</u>

FUNGAL INFECTION TRUST
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 30 APRIL 2022

APPENDIX

Publications supported by the Fungal Infection Trust in 2021

1. Stucky Hunter E, Wilopo B, Richardson MD, Kosmidis C, Denning DW. Effect of patient immunodeficiencies on the diagnostic performance of serological assays to detect *Aspergillus*-specific antibodies in chronic pulmonary aspergillosis. *Resp Med* 2021;178:106290.
2. Gago S, Overton NLD, Bowyer P. CRISPR-Cas9-Mediated Gene Silencing in Cultured Human Epithelia. *Methods Mol Biol* 2021;2260:37-47.
3. Koffi D, Ira V. Bonouman IV, Toure AO, Kouadjo F, M'boh N'GRE, Sylla K, Dosso M, Denning DW. Estimates of Serious Fungal Infection burden in Côte d'Ivoire and Country Health Profile. *J Mycol Med* 2021;31:101086.
4. Rozaliyani A, Setianingrum F, Azahra S, Abdullah A, Fatril AE, Rosianawati H, Burhan E, Handayani D, Arifin AR, Zaini J, Tugiran M, Adawiyah R, Syam R, Wibowo H, Wahyuningsih R, Kosmidis C, Denning DW. Performance of LDBio *Aspergillus* WB and ICT Antibody Detection in Chronic Pulmonary Aspergillosis. *J Fungi (Basel)* 2021;7(4):311.
5. Niazi-Ali S, Atherton GT, Walczak M, Denning DW. Drug–drug interaction database for safe prescribing of systemic antifungal agents. *Ther Adv Infectious Dis* 2021;8:1-9.
6. Kuate MPN, Nyasa R, Mandengue C, Tendongfor N, Bongomin F, Denning DW. Screening for acute disseminated histoplasmosis in HIV disease using urinary antigen detection enzyme immunoassay: A pilot study in Cameroon. *J Microbiol Methods* 2021;185:106226.
7. Pfavayi LT, Denning DW, Baker S, Sibanda EN, Mutapi F. Determining the burden of fungal infections in Zimbabwe. *Sci Rep* 2021;11:13240.
8. Denning DW. Diagnosing pulmonary aspergillosis is much easier than it used to be: A new diagnostic landscape. *Int J Lung Dis TB* 2021;25:525-536.
9. Sueiro-Olivares M, Scott J, Gago S, Petrovic D, Kouroussis E, Zivanovic J, Yu Y, Strobel M, Cunha C, Thomson D, Fortune-Grant R, Thusek S, Bowyer P, Beilhack A, Carvalho A, Bignell E, Filipovic MR, Amich J. Fungal and host protein persulfidation are functionally correlated and modulate both virulence and antifungal response. *PLoS Biol* 2021;19(6):e3001247.
10. Ben-Ghazzi N, Gago S, Thomson D, Seidel C, Moreno-Velsaquez S, Denning DW, Read N, Bowyer P. A high-resolution automated quantitative confocal microscopy approach to characterise *A. fumigatus* fate within airway phagolysosomes. *J Fungi* 2021;7:454.
11. Lakoh S, Orefuwa E, Kamara MN, Jiba DF, Kamara JB, Kpaka S, Denning DW. The burden of serious fungal infections in Sierra Leone: a national estimate. *Ther Adv Infectious Dis* 2021;8:1-12.
12. Wahyuningsih R, Adawiyah R, Sjam R, Prihartono J, At Wulandari E, Rozaliyani A, Ronny R, Imran D, Tugiran M, Siagian FE, Denning DW. Serious fungal disease incidence and prevalence in Indonesia. *Mycoses* 2021;64:1203-12.

FUNGAL INFECTION TRUST

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 30 APRIL 2022

13. Kamwiziku GK, Makangara JC, Orefuwa E, Denning DW. Serious fungal diseases in Democratic Republic of Congo - incidence and prevalence estimates. *Mycoses* 2021;64:1159-69.
14. Rowley J, Namvar S, Gago S, Labram B, Bowyer P, Richardson MD, Herrick SE. Differential Proinflammatory Responses to *Aspergillus fumigatus* by Airway Epithelial Cells In Vitro Are Protease Dependent. *J Fungi (Basel)* 2021;7(6):468.
15. Dorkenoo AM, Adjeteu-Toglozombio AK, Ocansey BK, Sossou E, Lack F, Denning DW. Estimated Burden Of Serious Fungal Infections In Togo. *Mycoses* 2021;64:1535–41.